Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.89 -0.03 (-3.63%)
Closing price 03:59 PM Eastern
Extended Trading
$0.91 +0.02 (+2.01%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRAX vs. SNSE, XFOR, SNPX, CSCI, PHXM, BCDA, NLSP, GLYC, LSB, and ADXN

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Sensei Biotherapeutics (SNSE), X4 Pharmaceuticals (XFOR), Synaptogenix (SNPX), COSCIENS Biopharma (CSCI), PHAXIAM Therapeutics (PHXM), BioCardia (BCDA), NLS Pharmaceutics (NLSP), GlycoMimetics (GLYC), LakeShore Biopharma (LSB), and Addex Therapeutics (ADXN). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

Sensei Biotherapeutics (NASDAQ:SNSE) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Sensei Biotherapeutics currently has a consensus target price of $90.00, indicating a potential upside of 889.01%. Virax Biolabs Group has a consensus target price of $3.00, indicating a potential upside of 237.04%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sensei Biotherapeutics is more favorable than Virax Biolabs Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensei Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Virax Biolabs Group's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sensei BiotherapeuticsN/A -66.72% -57.10%
Virax Biolabs Group N/A N/A N/A

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Virax Biolabs Group has higher revenue and earnings than Sensei Biotherapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.40
Virax Biolabs Group$10K386.30-$6.06MN/AN/A

Sensei Biotherapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 1 articles in the media. Sensei Biotherapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company Overall Sentiment
Sensei Biotherapeutics Neutral
Virax Biolabs Group Neutral

Summary

Virax Biolabs Group beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.86M$2.96B$5.57B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E RatioN/A21.1127.1820.15
Price / Sales386.30260.29417.49184.83
Price / CashN/A41.8337.0657.97
Price / Book0.717.748.085.60
Net Income-$6.06M-$54.96M$3.16B$248.50M
7 Day Performance2.90%6.04%3.77%5.15%
1 Month Performance-10.99%4.47%3.90%7.62%
1 Year Performance-18.34%6.12%34.22%21.56%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
2.8569 of 5 stars
$0.89
-3.6%
$3.00
+237.0%
-17.5%$3.86M$10K0.005Positive News
SNSE
Sensei Biotherapeutics
4.2052 of 5 stars
$8.75
+2.0%
$90.00
+928.6%
-30.1%$11.03MN/A-0.3840
XFOR
X4 Pharmaceuticals
4.6598 of 5 stars
$1.90
-0.3%
$72.33
+3,717.1%
-90.7%$10.97M$2.56M0.8880
SNPX
Synaptogenix
1.1849 of 5 stars
$7.85
+29.8%
$14.00
+78.3%
+82.2%$10.91MN/A-0.784Gap Up
High Trading Volume
CSCI
COSCIENS Biopharma
N/A$3.42
+0.6%
N/AN/A$10.77M$9.59M-0.5920
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58M$32.66M0.0049
BCDA
BioCardia
3.9919 of 5 stars
$2.04
+4.4%
$25.00
+1,128.5%
-21.6%$10.54M$60K-0.8740Positive News
NLSP
NLS Pharmaceutics
N/A$2.88
-0.7%
N/A+1,199.1%$10.37MN/A0.006
GLYC
GlycoMimetics
1.1836 of 5 stars
$0.16
-6.6%
N/A-99.4%$10.00M$10K-0.3450High Trading Volume
LSB
LakeShore Biopharma
0.7553 of 5 stars
$1.06
+3.4%
N/AN/A$9.82M$80.82M0.00773News Coverage
Gap Down
ADXN
Addex Therapeutics
2.8365 of 5 stars
$9.21
-2.2%
$30.00
+225.9%
+11.9%$9.76M$460K-27.0730High Trading Volume

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners